Under the Pape	rwork Reduction Act of 1995, no persons are requi	U.S. Patent and red to respond to a collection of in	Frademark Office; U.	hrough 06/30/2008. OMB 0651-0031 S. DEPARTMENT OF COMMERCE ontains a valid OMB control number.	
Request		Application Number	10/824,892		
for Continued Examination (RCE)		Filing Date	April 15, 200	April 15, 2004	
Transmittal		First Named Inventor	Etienne De	Etienne De Fontenay	
Address to: Mail Stop RCE		Art Unit	3683 - Conf	3683 - Confirm No. 7316	
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450		Examiner Name	Thomas J. V	Villiams	
		Attorney Docket Numb	oer 03161.1163	03	
Request for Contin	st for Continued Examination (RCE) u ued Examination (RCE) practice under 37 Cl sign application. See Instruction Sheet for RC	FR 1.114 does not apply to an	y utility or plant a	oplication filed prior to June 8,	
amendments applicant do amendment(e order in which they were file stered amendment(s) entered,	d unless applican applicant must re	t instructs otherwise. If quest non-entry of such	
	Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.				
i. [i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on				
ii. L	Other				
b. √ E	nclosed Amendment/Reply	D	ation Disclosure S	**************************************	
ii. [Affidavit(s)/ Declaration(s)		auon Disclosure s	` '	
2. Miscellaneous					
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a a. period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)					
	Other			(),104,210,0	
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 06-1205 I have enclosed a duplicate copy of this sheet					
i. RCE fee required under 37 CFR 1.17(e)					
ii. V Extension of time fee (37 CFR 1.136 and 1.17)					
	iii. Other				
c. Payment by credit card (Form PTO-2038 enclosed)					
	nation on this form may become public. Cr and authorization on PTO-2038.	redit card information shoul	d not be include	d on this form. Provide credit	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED					
Signature Name (Print/Type)	/Alicia A. Russo/		Date Registration No.	June 9, 2008	
Alloid A. Husso				46192	
I hereby certify that the		F MAILING OR TRANSMISS and States Postal Service with suffi		class mail in an envelope	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.					
Signature					

Date Name (Print/Type) This collection of information is required by 37 CFR 1.114. The information is required to obtain or relate a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 38 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete including glathening, propering, and sustaining the completed application from the USPTO. The wall way depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this bent, all both to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, P.G. Box 4450, Alexandria, V.A. 2231-1450, DON TSRN FEES FOR COMMILTED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Instruction Sheet for RCEs

(not to be submitted to the USPTO)

NOTES:

An RCE is not a new application, and filing an RCE will not result in an application being accorded a new filing date

Filing Qualifications:

The application must be a utility or plant application filed on or after June 8, 1995. The application cannot be a provisional application, a utility or plant application filed before June 8, 1995, a design application, or a patent under reexamination. See 37 CFR 1.114(e).

Filing Requirements:

Prosecution in the application must be closed. Prosecution is closed if the application is under appeal, or the last Office action is a final action, a notice of allowance, or an action that otherwise closes prosecution in the application (e.g., an Office action under Ex parte Quayle). See 37 CFR 1.114(b).

A submission and a fee are required at the time the RCE is filed. If eply to an Office action under 35 U.S.C. 132 is outstanding (e.g., the application is under final rejection), the submission must meet the reply requirements of 37 CFR 1.111. If there is no outstanding Office action, the submission can be an information disclosure statement, an amendment, new arguments, or new evidence. See 37 CFR 1.114(c). The submission may be a previously filed amendment (e.g., an amendment after final rejection).

WARNINGS:

Request for Suspension of Action:

All RCE filing requirements must be met before suspension of action is granted. A request for a suspension of action under 37 CFR 1.103(c) does <u>not</u> satisfy the submission requirement and does not permit the filing of the required submission to be suspended.

Improper RCE will NOT toll Any Time Period:

Before Appeal - If the RCE is improper (e.g., prosecution in the application is not closed or the submission or fee has not been filled) and the application is, not under appeal, the time period set forth lest Office action will continue to run and the application will be abandoned after the statutory time period has expired if a reply to the Office action is not timely facility.

Under Appeal - If the RCE is improper (e.g., the submission or the fee has not been filed) and the application is under appeal, the improper RCE is effective to withdraw the appeal. Withdrawal of the appeal results in the allowance or abandonment of the application depending on the status of the claims. If there are no allowed claims, the application is abandoned. If there is at least one allowed claims, the application is abandoned. If there is at least one allowed claim, the application will be passed to issue on the allowed claim(s). See MPEP 1215.01.

See MPEP 706.07(h) for further information on the RCE practice.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested information, the U.S. Patient and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patient.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (6 U.S.C. 552) and the Privacy Act (6 U.S. 6 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neoplations.
- A record in this system of records may be disclosed, as a routine use, to a Member of
 Congress submitting a request involving an individual, to whom the record pertains, when the
 individual has requested assistance from the Member with respect to the subject matter of the
 record
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.